Subscribe

News
Academy
Multimedia
Conferences
Publications
Partner Perspectives
Resources
Event Calendar
Subscribe

|Articles|June 20, 2019

Thrive or Die in the Omnichannel Era

Author(s)BioPharm Communications

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related Content

Pharmaceutical Executive daily

Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta

ByNicholas Jacobus

July 17th 2026

stock.adobe.com kidney

FDA Approves Fabhalta to Slow Kidney Function Decline in Primary IgAN in Adults

ByNicholas Jacobus

July 17th 2026

stock.adobe.com deal

Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement

ByNicholas Jacobus

July 17th 2026

Michael Oleksiw

From Dr. Google to Dr. Claude: Why the Most Important Patient Support Innovation Is Still Human Connection

ByMichael Oleksiw

July 17th 2026

David Hung

How Nuvation Bio Manages its Ongoing Clinical Trials

ByMike Hollan,David Hung

July 17th 2026

Trending on PharmExec

Jasper Therapeutics to Acquire Kira Pharmaceuticals in $132 Million Merger Agreement

FDA Approves Lipfendra to reduce LDL-C in Adults with Hypercholesterolemia

Pharmaceutical Executive Daily: FDA Grants Traditional Approval to Novartis's Fabhalta

How Nuvation Bio Manages its Ongoing Clinical Trials

FDA Approves Fabhalta to Slow Kidney Function Decline in Primary IgAN in Adults